Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer
Aim: The aim of this study is to characterize the effect of chemotherapy drug doxorubicin with neoadjuvant drug docetaxel for different molecular subtypes. Methods: A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combination...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-06-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/1533033820928435 |
| _version_ | 1828469591288840192 |
|---|---|
| author | Ling-Cheng Wang MD Ling-Sheng Wang BM Ai-Xia Li BM Zhen-Zong Shi MM Ya-Qiong Li MM Wei Huang MM Shi-Man Chen MM Fei Han BM De-Qiang Zhu BM |
| author_facet | Ling-Cheng Wang MD Ling-Sheng Wang BM Ai-Xia Li BM Zhen-Zong Shi MM Ya-Qiong Li MM Wei Huang MM Shi-Man Chen MM Fei Han BM De-Qiang Zhu BM |
| author_sort | Ling-Cheng Wang MD |
| collection | DOAJ |
| description | Aim: The aim of this study is to characterize the effect of chemotherapy drug doxorubicin with neoadjuvant drug docetaxel for different molecular subtypes. Methods: A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. Results: Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 + subtypes, did not show statistical significant differences to the treatment of combinational treatment for the complete response rate, including pathological complete response and clinical complete response. Comparing with luminal A and luminal B subtypes, the ERBB2 + and basal-like subtypes have better complete response and response rate rates. The disease-free survival rate and overall survival rate at 29 months after treatment did not show statistical significant differences among different subtypes of patients with breast cancer. Conclusion: The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel, and ERBB2 + and basal-like subtypes have better response rate and complete response rate. There is correlation of estrogen receptor and KI-67 level changes with response rate as well, where KI-67 high patients are more sensitive to the treatment. |
| first_indexed | 2024-12-11T04:41:32Z |
| format | Article |
| id | doaj.art-d681f490267f4fba82e7b7ca0d82c358 |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-12-11T04:41:32Z |
| publishDate | 2020-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-d681f490267f4fba82e7b7ca0d82c3582022-12-22T01:20:36ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382020-06-011910.1177/1533033820928435Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast CancerLing-Cheng Wang MD0Ling-Sheng Wang BM1Ai-Xia Li BM2Zhen-Zong Shi MM3Ya-Qiong Li MM4Wei Huang MM5Shi-Man Chen MM6Fei Han BM7De-Qiang Zhu BM8 Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Radiology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Otolaryngology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaAim: The aim of this study is to characterize the effect of chemotherapy drug doxorubicin with neoadjuvant drug docetaxel for different molecular subtypes. Methods: A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. Results: Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 + subtypes, did not show statistical significant differences to the treatment of combinational treatment for the complete response rate, including pathological complete response and clinical complete response. Comparing with luminal A and luminal B subtypes, the ERBB2 + and basal-like subtypes have better complete response and response rate rates. The disease-free survival rate and overall survival rate at 29 months after treatment did not show statistical significant differences among different subtypes of patients with breast cancer. Conclusion: The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel, and ERBB2 + and basal-like subtypes have better response rate and complete response rate. There is correlation of estrogen receptor and KI-67 level changes with response rate as well, where KI-67 high patients are more sensitive to the treatment.https://doi.org/10.1177/1533033820928435 |
| spellingShingle | Ling-Cheng Wang MD Ling-Sheng Wang BM Ai-Xia Li BM Zhen-Zong Shi MM Ya-Qiong Li MM Wei Huang MM Shi-Man Chen MM Fei Han BM De-Qiang Zhu BM Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer Technology in Cancer Research & Treatment |
| title | Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer |
| title_full | Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer |
| title_fullStr | Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer |
| title_full_unstemmed | Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer |
| title_short | Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer |
| title_sort | combinational treatment of doxorubicin with neoadjuvant docetaxel for different subtypes of patients with breast cancer |
| url | https://doi.org/10.1177/1533033820928435 |
| work_keys_str_mv | AT lingchengwangmd combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT lingshengwangbm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT aixialibm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT zhenzongshimm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT yaqionglimm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT weihuangmm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT shimanchenmm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT feihanbm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer AT deqiangzhubm combinationaltreatmentofdoxorubicinwithneoadjuvantdocetaxelfordifferentsubtypesofpatientswithbreastcancer |